Recent News

Ohr Pharmaceutical Announces Clinical Squalamine Eye Drop Program for Wet-AMD

Ohr Pharmaceutical Announces $1,050,000 Private Placement Led by Existing Investors

Ohr Pharmaceutical Enrolls First Three Patients at a New Clinical Site for Ongoing Phase 2b Cachexia Trial

Ohr Pharmaceutical Inc. Announces $244,000 Grant Award

Ohr Pharmaceutical Awarded U.S. Patent

Ohr Pharmaceutical Awarded Japanese Patent

Ohr Pharmaceutical Moves Headquarters to New York

Ohr Pharmaceutical Bolsters Senior Management Team

Ohr Pharmaceutical Raises $1 Million From Existing Investors

Ohr Pharmaceutical presents new interim phase 2 clinical data showing its OHR/AVR 118 drug to be safe, effective treatment of severe wasting disorder (Cachexia) in late stage cancer patients

Ohr Pharmaceutical Announces Presentation of Interim Phase II Cachexia Data

Ohr Pharmaceutical Data Review Supports the Strong Potential of Its Lead Drug OHR/AVR118 for Cachexia

Ohr Pharmaceutical (OTC BB: OHRP) Data Review Supports Strong Potential of EVIZON(TM) for Wet AMD

Ohr Pharmaceutical (OTC BB: OHRP) CEO Announces Completion of Biotech Transformation with Acquisition of Phase II Drugs